FDA's Hatch-Waxman Group To Tackle Wider Generics Issues
When the U.S. Food and Drug Administration's new working group meets to discuss modernizing the Hatch-Waxman Act and increasing generic competition, experts expect it to touch on a wide range of...To view the full article, register now.
Already a subscriber? Click here to view full article